Carl Icahn makes a big move into mid-size drugmaker Forest Laboratories (FRX +1.9%) - a 6.5%...


Carl Icahn makes a big move into mid-size drugmaker Forest Laboratories (FRX +1.9%) - a 6.5% stake - and will nominate four directors for its board. Forest faces patent expirations for antidepressant Lexapro and its Alzheimer's medicine Namenda.

Comments (1)
  • Bret Jensen
    , contributor
    Comments (14030) | Send Message
     
    Figured this might happen. Forest Labs is way undervalued....seekingalpha.com/artic...
    13 Jun 2011, 04:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs